Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The RAPS store will be under maintenance Saturday, 7 December between 6 AM and 12 PM. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 22 December 2017 | By Michael Mezher
The US Food and Drug Administration (FDA) on Friday released a proposal that would allow medical device manufacturers to submit malfunction reports for certain devices to the agency in summary format on a quarterly basis.
In 2007, the Food and Drug Administration Amendments Act made changes to FDA's reporting requirements for device malfunctions to allow for summary reporting of malfunction for Class I and Class II devices "that are not permanently implantable, life supporting or life sustaining" on a quarterly basis.
However, since 2011 FDA has required individual malfunction reports for such devices, unless a reporting exemption or variance was granted for specific devices, or until the agency gave further notice on summary reporting criteria.
In 2015, FDA launched a pilot initiative to explore criteria for quarterly summary reporting for low-risk Class I and Class II devices.
Now that the pilot has concluded, FDA says it plans to finalize a voluntary program for quarterly malfunction medical device reporting (MDR) in summary format.
"While manufacturers must report certain device malfunctions to the FDA, these individual reports often describe the same problem, creating a process where the FDA conducts duplicate reviews of common malfunctions," said Center for Devices and Radiological Health Director Jeffrey Shuren.
According to Shuren, the summary reporting proposal will allow the agency more easily identify potential safety issues while reducing the amount of recourses required to review malfunction reports.
During the pilot, FDA says participants were able to reduce the volume of reports by 87%, "while preserving essential information regarding the context around malfunction events."
In a shift from the pilot, FDA says it will establish a list of product codes that would be eligible for summary reporting, including some Class III devices, once its proposal is finalized. The agency also says that it will generally not consider devices in new product codes to be eligible for summary reporting for two years, unless the new product code was issued for administrative purposes only.
FDA says it has developed six principles to support quarterly, summary reporting:
However, FDA says it will still require individual malfunction reports for malfunctions that are likely to cause or contribute to a death or serious injury within 30 calendar days, and notes that it may require individual reporting in other situations to address public health issues, or bar require specific manufacturers to submit individual reports if they fail to comply with the agency's reporting requirements.
Federal Register Notice
Tags: Malfunction, Medical Device Reporting, MDR
Regulatory Focus newsletters
All the biggest regulatory news and happenings.